OBJECTIVE: Radiosurgery is an appealing alternative management strategy for selected patients with biopsy-proved pineal parenchymal tumors. The purpose of this report was to clarify its role in conjunction with other surgical, radiation, and medical approaches. METHODS: We retrospectively evaluated 16 patients who had undergone radiosurgery as the primary or adjuvant treatment for pineal parenchymal tumors. Ten patients (62.5%) had pineocytomas, two (12.5%) had mixed pineocytoma and pineoblastoma, and four (25%) had pineoblastomas. The mean marginal dose was 15 Gy, and the mean tumor volume was 5.0 cm(3). The mean follow-up periods from the time of diagnosis or the time of radiosurgery were 61 and 52 months, respectively. RESULTS: The overall actuarial 2- and 5-year survival rates after diagnosis were 75.0 and 66.7%, respectively. In 14 patients who were evaluated with imaging, 4 (29%) demonstrated complete remission, 8 (57%) had partial remission, 2 (14%) had no change, and no patient had local progression. The local tumor control rate (complete remission, partial remission, or no change) was 100%. Five patients died during follow-up. One patient with a pineocytoma and three patients with pineoblastomas died secondary to leptomeningeal or extracranial spread tumor. No cause of death was established for one patient. Two patients developed adverse radiation effects after radiosurgery. CONCLUSION: Our initial experience suggests that stereotactic radiosurgery is a valuable primary management modality for patients with pineocytomas. As adjuvant therapy, radiosurgery may be used to boost local tumor dose during multimodality management of malignant pineal parenchymal tumors.
OBJECTIVE: Radiosurgery is an appealing alternative management strategy for selected patients with biopsy-proved pineal parenchymal tumors. The purpose of this report was to clarify its role in conjunction with other surgical, radiation, and medical approaches. METHODS: We retrospectively evaluated 16 patients who had undergone radiosurgery as the primary or adjuvant treatment for pineal parenchymal tumors. Ten patients (62.5%) had pineocytomas, two (12.5%) had mixed pineocytoma and pineoblastoma, and four (25%) had pineoblastomas. The mean marginal dose was 15 Gy, and the mean tumor volume was 5.0 cm(3). The mean follow-up periods from the time of diagnosis or the time of radiosurgery were 61 and 52 months, respectively. RESULTS: The overall actuarial 2- and 5-year survival rates after diagnosis were 75.0 and 66.7%, respectively. In 14 patients who were evaluated with imaging, 4 (29%) demonstrated complete remission, 8 (57%) had partial remission, 2 (14%) had no change, and no patient had local progression. The local tumor control rate (complete remission, partial remission, or no change) was 100%. Five patients died during follow-up. One patient with a pineocytoma and three patients with pineoblastomas died secondary to leptomeningeal or extracranial spread tumor. No cause of death was established for one patient. Two patients developed adverse radiation effects after radiosurgery. CONCLUSION: Our initial experience suggests that stereotactic radiosurgery is a valuable primary management modality for patients with pineocytomas. As adjuvant therapy, radiosurgery may be used to boost local tumor dose during multimodality management of malignant pineal parenchymal tumors.
Authors: Mohammad Maarouf; Faycal El Majdoub; Christian Bührle; Jürgen Voges; Ralph Lehrke; Martin Kocher; Stefan Hunsche; Harald Treuer; Volker Sturm Journal: Strahlenther Onkol Date: 2010-02-22 Impact factor: 3.621
Authors: S Chibbaro; F Di Rocco; O Makiese; A Reiss; P Poczos; G Mirone; F Servadei; B George; P Crafa; M Polivka; A Romano Journal: Neurosurg Rev Date: 2012-01-19 Impact factor: 3.042
Authors: Aaron J Clark; Michael E Sughrue; Michael E Ivan; Derick Aranda; Martin J Rutkowski; Ari J Kane; Susan Chang; Andrew T Parsa Journal: J Neurooncol Date: 2010-05-12 Impact factor: 4.130
Authors: Salvador Villà; Robert C Miller; Marco Krengli; Huda Abusaris; Brigitta G Baumert; Stephanie Servagi-Vernat; Sefik Igdem; Anna Lucas; Susanna Boluda; René O Mirimanoff Journal: Clin Transl Oncol Date: 2012-08-23 Impact factor: 3.405
Authors: David R Raleigh; David A Solomon; Shane A Lloyd; Ann Lazar; Michael A Garcia; Penny K Sneed; Jennifer L Clarke; Michael W McDermott; Mitchel S Berger; Tarik Tihan; Daphne A Haas-Kogan Journal: Neuro Oncol Date: 2016-06-09 Impact factor: 12.300
Authors: Christian Senft; Andreas Raabe; Elke Hattingen; Daniel Sommerlad; Volker Seifert; Kea Franz Journal: Neurosurg Rev Date: 2008-02-12 Impact factor: 3.042